<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00755079</url>
  </required_header>
  <id_info>
    <org_study_id>B4162-C</org_study_id>
    <nct_id>NCT00755079</nct_id>
  </id_info>
  <brief_title>Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Determine the Effect of an Oral Beta-2 Agonist on Respiratory Muscle Strength in Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the effect of administration of the oral
      beta-2 adrenergic agonist, albuterol, on respiratory muscle strength in individuals with
      cervical (neck) and high thoracic (upper back) spinal cord injury and to compare findings
      with those obtained in a demographically matched group that will receive placebo.
      Participation in this study will involve 12 weeks of pharmacological intervention during
      which participants will be randomized to receive either oral albuterol 4mg twice daily or
      placebo. All investigators and study participants will be blinded to randomization by our
      research pharmacy. Participation in the study will require study subjects to come to our lab
      for the total of 2 visits (at baseline and after week 12), during which a series of tests
      will be performed to assess their respiratory muscle strength and pulmonary function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inspiratory Respiratory Muscle Strength</measure>
    <time_frame>Outcome will be measured at baseline, prior to intervention, and after 12 weeks of twice daily drug treatment.</time_frame>
    <description>Respiratory muscle strength as measured by maximal inspiratory and pressures at the mouth.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expiratory Respiratory Muscle Strength</measure>
    <time_frame>Outcome will be measured at baseline, prior to intervention, and after 12 weeks of twice daily drug treatment.</time_frame>
    <description>Respiratory Muscle Strength defines as Maximal expiratory muscle strength at the mouth.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>group of persons with spinal cord injury will receive blinded placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group of persons with spinal cord injury will receive blinded beta-2 adrenergic agonist capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>extended release beta-2 adrenergic agonist</intervention_name>
    <description>Albuterol extended release belongs to a class of drugs known as bronchodilators. It works in the airways by opening breathing passages and relaxing muscles.</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic Spinal Cord Injury (&gt;1 year post-injury)

          -  All American Spinal Injury Association (ASIA) classifications

          -  High Paraplegia (level of injury T1-T6)

          -  Tetraplegia (level of injury C2-C8, non-ventilator dependent)

        Exclusion Criteria:

          -  history of asthma

          -  uncontrolled hypertension or cardiovascular disease

          -  those using beta-2 adrenergic agonists

          -  epilepsy or seizure disorder

          -  hyperthyroidism

          -  chronic corticosteroid use

          -  those taking monoamine oxidase inhibitors or Tricyclic antidepressants for depression

          -  hypersensitivity to albuterol or any of its' delete components

          -  pregnancy

          -  use of ergogenic aids or supplements with anabolic characteristics including, but not
             limited to:

               -  creatine monohydrate

               -  anabolic steroids (e.g., testosterone)

               -  growth hormone and their analogs and/or derivatives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg Schilero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Bronx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Bronx</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2008</study_first_submitted>
  <study_first_submitted_qc>September 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <results_first_submitted>June 16, 2014</results_first_submitted>
  <results_first_submitted_qc>June 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2014</results_first_posted>
  <last_update_submitted>February 24, 2015</last_update_submitted>
  <last_update_submitted_qc>February 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal cord injury</keyword>
  <keyword>beta-2 agonist</keyword>
  <keyword>respiratory muscle strength</keyword>
  <keyword>pulmonary function test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic Agents</mesh_term>
    <mesh_term>Adrenergic Agonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Control</title>
          <description>group of persons with spinal cord injury will receive blinded placebo capsule
placebo: An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.</description>
        </group>
        <group group_id="P2">
          <title>Active Drug</title>
          <description>group of persons with spinal cord injury will receive blinded beta-2 adrenergic agonist capsule
extended release beta-2 adrenergic agonist: Albuterol extended release belongs to a class of drugs known as bronchodilators. It works in the airways by opening breathing passages and relaxing muscles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>group of persons with spinal cord injury will receive blinded placebo capsule
placebo: An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.</description>
        </group>
        <group group_id="B2">
          <title>Active Drug</title>
          <description>group of persons with spinal cord injury will receive blinded beta-2 adrenergic agonist capsule
extended release beta-2 adrenergic agonist: Albuterol extended release belongs to a class of drugs known as bronchodilators. It works in the airways by opening breathing passages and relaxing muscles.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.24" spread="9.53"/>
                    <measurement group_id="B2" value="42.75" spread="14.74"/>
                    <measurement group_id="B3" value="42.48" spread="12.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Inspiratory Respiratory Muscle Strength</title>
        <description>Respiratory muscle strength as measured by maximal inspiratory and pressures at the mouth.</description>
        <time_frame>Outcome will be measured at baseline, prior to intervention, and after 12 weeks of twice daily drug treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Control</title>
            <description>group of persons with spinal cord injury will receive blinded placebo capsule
placebo: An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.</description>
          </group>
          <group group_id="O2">
            <title>Active Drug</title>
            <description>group of persons with spinal cord injury will receive blinded beta-2 adrenergic agonist capsule
extended release beta-2 adrenergic agonist: Albuterol extended release belongs to a class of drugs known as bronchodilators. It works in the airways by opening breathing passages and relaxing muscles.</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Respiratory Muscle Strength</title>
          <description>Respiratory muscle strength as measured by maximal inspiratory and pressures at the mouth.</description>
          <units>cmH2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Maximal Inspiratory Pressure Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.35" spread="18.07"/>
                    <measurement group_id="O2" value="79.19" spread="29.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximal Inspiratory Pressure 12wk Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.31" spread="24.51"/>
                    <measurement group_id="O2" value="91.69" spread="32.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Expiratory Respiratory Muscle Strength</title>
        <description>Respiratory Muscle Strength defines as Maximal expiratory muscle strength at the mouth.</description>
        <time_frame>Outcome will be measured at baseline, prior to intervention, and after 12 weeks of twice daily drug treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Control</title>
            <description>group of persons with spinal cord injury will receive blinded placebo capsule
placebo: An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.</description>
          </group>
          <group group_id="O2">
            <title>Active Drug</title>
            <description>group of persons with spinal cord injury will receive blinded beta-2 adrenergic agonist capsule
extended release beta-2 adrenergic agonist: Albuterol extended release belongs to a class of drugs known as bronchodilators. It works in the airways by opening breathing passages and relaxing muscles.</description>
          </group>
        </group_list>
        <measure>
          <title>Expiratory Respiratory Muscle Strength</title>
          <description>Respiratory Muscle Strength defines as Maximal expiratory muscle strength at the mouth.</description>
          <units>cmH2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Maximal Expiratory Pressure Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.65" spread="36.82"/>
                    <measurement group_id="O2" value="70.38" spread="35.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximal Expiratory Pressure 12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.31" spread="30.12"/>
                    <measurement group_id="O2" value="77.44" spread="37.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>group of persons with spinal cord injury will receive blinded placebo capsule
placebo: An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.</description>
        </group>
        <group group_id="E2">
          <title>Active Drug</title>
          <description>group of persons with spinal cord injury will receive blinded beta-2 adrenergic agonist capsule
extended release beta-2 adrenergic agonist: Albuterol extended release belongs to a class of drugs known as bronchodilators. It works in the airways by opening breathing passages and relaxing muscles.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Cramping</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joshua Hobson, MS</name_or_title>
      <organization>VAHSRD</organization>
      <phone>(718) 584-9000 ext 3129</phone>
      <email>joshua.hobson@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

